Table 3.

Stage-stratified Cox regression analyses of NLR in cancer patients with and without Af

	Af group (n = 753)		Non-Af group (n = 17 464)
	HR (95% CI)	P-value	HR (95% CI)	P-value
Univariate analysis
Middle NLR group (5 ≤ NLR ≤ 15)	0.643 (0.081–5.101)	0.676	1.426 (0.659–3.083)	0.367
High NLR group (NLR > 15)	4.025 (0.475–34.080)	0.201	6.240 (1.877–20.741)	0.003
Multivariate analysis
Middle NLR group (5 ≤ NLR ≤ 15)	0.709 (0.087–5.768)	0.747	1.503 (0.695–3.250)	0.301
High NLR group (NLR > 15)	11.598 (0.953–141.181)	0.055	7.877 (2.351–26.389)	0.001
Age, years, per 1 increase	1.020 (0.965–1.077)	0.491	1.048 (1.019–1.078)	0.001
Hypertension	1.414 (0.399–5.018)	0.592	1.856 (1.002–4.437)	0.0049
Dyslipidaemia	2.142 (0.638–7.194)	0.218	1.294 (0.656–2.552)	0.456
Diabetes mellitus	1.162 (0.374609)	0.795	1.696 (0.915–3.144)	0.093
Drinking history	0.608 (0.129–2.864)	0.530	0.956 (0.373–2.451)	0.925

Af, atrial fibrillation; CI, confidence interval; HR, hazard ratio; NLR, neutrophil-to-lymphocyte ratio.